Additionally, bavdegalutamide has demonstrated superior inhibition of tumor growth compared with enzalutamide in various AR-positive prostate cancer xenograft models in mice, solidifying its effectiveness [48,50,51,52]. The gene discussed is AR; the disease is prostate carcinoma.